Astria Therapeutics Inc ATXS.OQ ATXS.O is expected to show a rise in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2025
The United States of America-based company is expected to report revenue of $10.667 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Astria Therapeutics Inc is for a loss of 39 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Astria Therapeutics Inc is $22.50, about 44.8% above its last closing price of $12.43
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.59 | -0.59 | -0.57 | Beat | 2.7 |
Mar. 31 2025 | -0.48 | -0.48 | -0.58 | Missed | -21.1 |
Dec. 31 2024 | -0.45 | -0.45 | -0.20 | Beat | 55.7 |
Sep. 30 2024 | -0.44 | -0.42 | -0.42 | Met | 0.4 |
Jun. 30 2024 | -0.39 | -0.38 | -0.43 | Missed | -11.7 |
Mar. 31 2024 | -0.37 | -0.36 | -0.38 | Missed | -4.4 |
Dec. 31 2023 | -0.78 | -0.78 | -0.94 | Missed | -20.5 |
Sep. 30 2023 | -0.46 | -0.49 | -0.63 | Missed | -29.6 |
This summary was machine generated November 7 at 13:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)